Although it is necessary to investigate the underlying causes of the differences in PD-L1 and CD163 expression in the TME during brachytherapy, this study may increase our understanding of tumor-associated immunity and aid in the development of treatment methods that exploit this immunity in RT for cervical cancer. This evidence concerns the gene CD163 and neoplasm.